Acute Exercise and NK Cell Regulation in Tissue and Circulation After IL-6R Blockade
NCT ID: NCT04616235
Last Updated: 2022-08-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-03-15
Study Completion Date
2021-10-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is a randomized controlled trial studying the acute effect of intense aerobic exercise upon NK (Natural Killer) cell activation and appetite-regulation in human participants with or without concommitant IL-6R receptor blockade (Tocilizumab)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Characterization of CD8+ T Cells After Supramaximal Exercise
NCT06484101
Exercise Induced CD8+ T Cell Recruitment and Characterization of Function and Phenotype of These Cells
COMPLETED
NA
Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00023985
Lung Cancer
COMPLETED
PHASE1
Fase I Clinical Trial on NK Cells for COVID-19
NCT04634370
Covid19
Sars-cov 2
UNKNOWN
PHASE1
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
NCT02479698
Acquired Immunodeficiency Syndrome
BK Virus Infection
Human Immunodeficiency Virus
+5 more
RECRUITING
PHASE2
Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19
NCT04762186
Moderate COVID-19-infection
TERMINATED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
Primary Objective:
* To explore the association between acute exercise, IL-6 blockade and NK regulation in circulation.
* To explore whether exercise activated NK-cells have a unique phenotype using single cell RNA sequencing.
Secondary Objectives:
* To explore the effect of acute aerobic exercise on NK cell number and activity in circulation, muscle and adipose tissue, in healthy young males, in order to indirectly explore exercise as an anti-cancer remedy.
* To assess the kinetics of the NK-cell response and, if possible, chronologically investigate the appearance and whereabouts of the activated NK-cells.
Explorative Objectives
* To establish a reproducible protocol for tracking various immune-cells and their involvement in the acute exercise response in humans
* To investigate novel signal molecules released from muscle during exercise with immunological importance.
* To investigate the possible role of exercise induced IL-6 on subjective feelings of hunger and satiety post exercise and food intake. • To explore the effect of IL-6 receptor blockade on the exercise proteome and metabolome, using mass spectrometry
Methods:
30 healthy recreationally active young males will be included in this acute exercise study in which NK-cell kinetic and regulation will be studied in response to acute aerobic exercise and IL-6R blockade or placebo.
The study consists of 2 visits. At inclusion (visit 1) all subjects will undergo assessment encompassing: baseline medical screening (auscultation, blood pressure, ECG), determination of body composition (DXA), cardiovascular fitness (VO2max) and standard fasting blood-biochemistry which will be analyzed immediately. Visit 2 will consist of a muscle and fat biopsy from the dominant leg and abdominal subcutaneous-fat depot respectively (both under resting conditions), which will then act as reference tissue for the further tissue analysis. Then, a 18G antecubital peripheral venous access will be secured prior to commencing with IL-6R infusion. 2 hours after the infusion procedure the subjects will undergo an acute exercise protocol. Subjects will then be challenged by a high intensity acute aerobic exercise bout, utilizing a bicycle ergometer. Blood samples will be drawn prior to the infusion and exercise, during exercise, as well as immediately, ½, 1, 1½ and 2h post exercise and up 4h post exercise in the appetite regulation substudy. Blood samples will immediately be analyzed for leucocyte count and differentiation as well as plasma biochemistry. In addition, blood samples will be utilized for NK cell isolation with subsequent single cell RNA sequencing, immune cell distribution and killing capacity towards cancer cells. Furthermore, plasma samples will be collected and frozen for later determination of cortisol, prolactin and circulating cytokines, including but not limited to IL-6 and G-CSF. Lastly, in the appetite substudy, insulin, GLP-1 and free fatty acids will be measured.
Tissue samples will be obtained 2h post exercise for optimizing gene-expression analysis. Both muscle and adipose tissue samples will be analyzed for inflammatory and anti-inflammatory markers, NK cell content and phenotyping of these NK cells using markers obtained from single cell sequencing, conducted on the blood-borne NK-cells. Furthermore, immune cell infiltration will be assessed using histology. All tissue samples will be obtained using a Bergström needle under sterile conditions during local anesthesia in order to minimize any sample-related discomfort or infection.
After the tissue sample, an ad libitum meal will be served, the subjects can eat as much can, but are instructed not to overconsume as any leftover food can be taken home. Paracetamol (1.5g) will be given to asses gastric emptying.
All participants will undergo the 2 study visits at the same approximate time of the day (9.00 a.m.) After completion of the study, any left-over material will be transferred to the CFAS biobank.
Subjects: Included subjects will be 30 recreationally active, moderately trained, healthy young males aged 18-40 years. Exclusion criteria are: cardiovascular, rheumatologic and metabolic disease, elite sports or high aerobic training status. Chronic use of nonsteroidal anti-inflammatory drug (NSAID) or other immunosuppressants.
Intervention: Subjects will be randomized to acute exercise, with (n=15) or without (n=15) prior IL-6R blockade. The exercise intervention will consist of a highly taxing ≈45 minutes interval based, aerobic exercise bout, conducted on a stationary bicycle ergometer. After an initial 5-minute warmup at 50-60% of HRmax, subjects will undergo seven, verbally encouraged, 3-minute intervals at above 90% HRmax, interspersed by 3 minutes of low intensity pedaling. Blood samples will be drawn before, during as well as immediately, ½, 1, 1½ and 2h post exercise together with tissue sampling at the 2h time-point.
To assess appetite regulation, further blood samples will be drawn from 2h-4h post exercise.
Statistical considerations: Based on data from our pilot study, we anticipate a ≈ 45 % lower maximal NK cell mobilization in the IL6R inhibition group compared to CON and a 29 % difference in NK cell nadir with the lowest values obtained in the IL6R inhibition group. Assuming a 5%-significance level in two-sided tests, we need to include 9 patients in each group to achieve 90% power for detecting a relative difference of 45 % in the intervention-group. To account for potential dropouts/excluded, due to the somewhat invasive setup, we will include a total of 30 patients (15 per group).
Recruitment: Subjects will be recruited through forsøgsperson.dk or similar sites alongside advertising at relevant sites.
Subjects will contact us at CFAS and will be given the choice whether to receive study information pr. telephone (thereby denying the option of a bystander) or a face to face meeting at CFAS. All this information will be given by the primary investigator. If the subject is interested in hearing more of the study, relevant documents will be emailed. If the subject is interested in joining the study after having received written or oral information, he will have 24h to consider study participation. When the subject has been informed either by telephone or face to face and accepts study participation, he will be invited to visit 1 where written and informed consent will be obtained (or signed and brought from home by the participant).
Risks and adverse reactions: Subjects may experience minor discomfort with regard to blood and tissue samples. The blood volume drawn is negligible and will not be associated with any health risk. All sampling of tissues will be performed under sterile conditions during local anesthesia and will thus be associated with little pain or discomfort and very little risk of infection. During exercise testing, participants may experience shortness of breath.
IL-6R inhibition is generally well tolerated with only few side-effects. The dose of paracetamol is low and is not associated with any risk.
Contact information of the involved medical doctor will be given to participants at study inclusion, so that any adverse event can be reported and solved.
Dissemination of study results: Both positive, negative and inconclusive results will be published in relevant international scientific journals.
Ethical consideration: The project is expected to cause limited risks, side effects and discomfort. All procedures will be performed by experienced physicians and physiologists with relevant safety. Tocilizumab is generally well tolerated and the dose of paracetamol is low. Included subjects may at any time, and without justification, retract their consent of study participation. We believe that the project is important and will contribute with critical new information on the IL-6 modifiable NK-cell response to acute exercise both in circulation and in adipose and muscle tissue (as there is currently very limited knowledge on the latter).
The study is considered a toolbox-study by Lægemiddelstyrelsen, and hence not at pharmaceutical study
Primary Objective:
* To explore the association between acute exercise, IL-6 blockade and NK regulation in circulation.
* To explore whether exercise activated NK-cells have a unique phenotype using single cell RNA sequencing.
Secondary Objectives:
* To explore the effect of acute aerobic exercise on NK cell number and activity in circulation, muscle and adipose tissue, in healthy young males, in order to indirectly explore exercise as an anti-cancer remedy.
* To assess the kinetics of the NK-cell response and, if possible, chronologically investigate the appearance and whereabouts of the activated NK-cells.
Explorative Objectives
* To establish a reproducible protocol for tracking various immune-cells and their involvement in the acute exercise response in humans
* To investigate novel signal molecules released from muscle during exercise with immunological importance.
* To investigate the possible role of exercise induced IL-6 on subjective feelings of hunger and satiety post exercise and food intake. • To explore the effect of IL-6 receptor blockade on the exercise proteome and metabolome, using mass spectrometry
Methods:
30 healthy recreationally active young males will be included in this acute exercise study in which NK-cell kinetic and regulation will be studied in response to acute aerobic exercise and IL-6R blockade or placebo.
The study consists of 2 visits. At inclusion (visit 1) all subjects will undergo assessment encompassing: baseline medical screening (auscultation, blood pressure, ECG), determination of body composition (DXA), cardiovascular fitness (VO2max) and standard fasting blood-biochemistry which will be analyzed immediately. Visit 2 will consist of a muscle and fat biopsy from the dominant leg and abdominal subcutaneous-fat depot respectively (both under resting conditions), which will then act as reference tissue for the further tissue analysis. Then, a 18G antecubital peripheral venous access will be secured prior to commencing with IL-6R infusion. 2 hours after the infusion procedure the subjects will undergo an acute exercise protocol. Subjects will then be challenged by a high intensity acute aerobic exercise bout, utilizing a bicycle ergometer. Blood samples will be drawn prior to the infusion and exercise, during exercise, as well as immediately, ½, 1, 1½ and 2h post exercise and up 4h post exercise in the appetite regulation substudy. Blood samples will immediately be analyzed for leucocyte count and differentiation as well as plasma biochemistry. In addition, blood samples will be utilized for NK cell isolation with subsequent single cell RNA sequencing, immune cell distribution and killing capacity towards cancer cells. Furthermore, plasma samples will be collected and frozen for later determination of cortisol, prolactin and circulating cytokines, including but not limited to IL-6 and G-CSF. Lastly, in the appetite substudy, insulin, GLP-1 and free fatty acids will be measured.
Tissue samples will be obtained 2h post exercise for optimizing gene-expression analysis. Both muscle and adipose tissue samples will be analyzed for inflammatory and anti-inflammatory markers, NK cell content and phenotyping of these NK cells using markers obtained from single cell sequencing, conducted on the blood-borne NK-cells. Furthermore, immune cell infiltration will be assessed using histology. All tissue samples will be obtained using a Bergström needle under sterile conditions during local anesthesia in order to minimize any sample-related discomfort or infection.
After the tissue sample, an ad libitum meal will be served, the subjects can eat as much can, but are instructed not to overconsume as any leftover food can be taken home. Paracetamol (1.5g) will be given to asses gastric emptying.
All participants will undergo the 2 study visits at the same approximate time of the day (9.00 a.m.) After completion of the study, any left-over material will be transferred to the CFAS biobank.
Subjects: Included subjects will be 30 recreationally active, moderately trained, healthy young males aged 18-40 years. Exclusion criteria are: cardiovascular, rheumatologic and metabolic disease, elite sports or high aerobic training status. Chronic use of nonsteroidal anti-inflammatory drug (NSAID) or other immunosuppressants.
Intervention: Subjects will be randomized to acute exercise, with (n=15) or without (n=15) prior IL-6R blockade. The exercise intervention will consist of a highly taxing ≈45 minutes interval based, aerobic exercise bout, conducted on a stationary bicycle ergometer. After an initial 5-minute warmup at 50-60% of HRmax, subjects will undergo seven, verbally encouraged, 3-minute intervals at above 90% HRmax, interspersed by 3 minutes of low intensity pedaling. Blood samples will be drawn before, during as well as immediately, ½, 1, 1½ and 2h post exercise together with tissue sampling at the 2h time-point.
To assess appetite regulation, further blood samples will be drawn from 2h-4h post exercise.
Statistical considerations: Based on data from our pilot study, we anticipate a ≈ 45 % lower maximal NK cell mobilization in the IL6R inhibition group compared to CON and a 29 % difference in NK cell nadir with the lowest values obtained in the IL6R inhibition group. Assuming a 5%-significance level in two-sided tests, we need to include 9 patients in each group to achieve 90% power for detecting a relative difference of 45 % in the intervention-group. To account for potential dropouts/excluded, due to the somewhat invasive setup, we will include a total of 30 patients (15 per group).
Recruitment: Subjects will be recruited through forsøgsperson.dk or similar sites alongside advertising at relevant sites.
Subjects will contact us at CFAS and will be given the choice whether to receive study information pr. telephone (thereby denying the option of a bystander) or a face to face meeting at CFAS. All this information will be given by the primary investigator. If the subject is interested in hearing more of the study, relevant documents will be emailed. If the subject is interested in joining the study after having received written or oral information, he will have 24h to consider study participation. When the subject has been informed either by telephone or face to face and accepts study participation, he will be invited to visit 1 where written and informed consent will be obtained (or signed and brought from home by the participant).
Risks and adverse reactions: Subjects may experience minor discomfort with regard to blood and tissue samples. The blood volume drawn is negligible and will not be associated with any health risk. All sampling of tissues will be performed under sterile conditions during local anesthesia and will thus be associated with little pain or discomfort and very little risk of infection. During exercise testing, participants may experience shortness of breath.
IL-6R inhibition is generally well tolerated with only few side-effects. The dose of paracetamol is low and is not associated with any risk.
Contact information of the involved medical doctor will be given to participants at study inclusion, so that any adverse event can be reported and solved.
Dissemination of study results: Both positive, negative and inconclusive results will be published in relevant international scientific journals.
Ethical consideration: The project is expected to cause limited risks, side effects and discomfort. All procedures will be performed by experienced physicians and physiologists with relevant safety. Tocilizumab is generally well tolerated and the dose of paracetamol is low. Included subjects may at any time, and without justification, retract their consent of study participation. We believe that the project is important and will contribute with critical new information on the IL-6 modifiable NK-cell response to acute exercise both in circulation and in adipose and muscle tissue (as there is currently very limited knowledge on the latter).
The study is considered a toolbox-study by Lægemiddelstyrelsen, and hence not at pharmaceutical study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interleukin-6 Inhibition
Physical Stress
Appetitive Behavior
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
The IL-6R receptor blockade infusion will have bag concealment so that neither the scientific staff or the subject will know if Tocilizumab or saline (placebo) is given and we do not expect the subjects to "feel" the infusion or the results of the infusion.
All scientific staff will be blinded to group allocation using encryption. Only once all data have been obtained (histology, blood analysis, gene-expression, Western Blot, Flow cytometry, single cell RNA sequencing) concealment will be broken so that statistical analysis can be conducted.
All scientific staff will be blinded to group allocation using encryption. Only once all data have been obtained (histology, blood analysis, gene-expression, Western Blot, Flow cytometry, single cell RNA sequencing) concealment will be broken so that statistical analysis can be conducted.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CON
This group will do intense aerobic exercise without concomitant IL-6R blockade
Group Type
PLACEBO_COMPARATOR
Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour
Intervention Type
OTHER
The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
BLOCK
This group will do intense aerobic exercise with concomitant IL-6R blockade
Group Type
ACTIVE_COMPARATOR
Tocilizumab Injectable Product
Intervention Type
DRUG
The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab Injectable Product
The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
Intervention Type
DRUG
Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour
The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* recreationally active
* moderately trained
* healthy young males aged 18-40 years
* BMI from 18-30 kg·m2
* moderately trained
* healthy young males aged 18-40 years
* BMI from 18-30 kg·m2
Exclusion Criteria
* Cardiovascular disease
* Rheumatologic disease
* Metabolic disease,
* Elite sports or high aerobically training status (VO2max\>60ml O2/min/kg),
* Frequent/chronic use of medications affecting physical performance or inflammation (NSAIDS, DMARDS)
* Rheumatologic disease
* Metabolic disease,
* Elite sports or high aerobically training status (VO2max\>60ml O2/min/kg),
* Frequent/chronic use of medications affecting physical performance or inflammation (NSAIDS, DMARDS)
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
MALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andreas Kraag Kraag Ziegler
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas K Ziegler, PhD
Role: PRINCIPAL_INVESTIGATOR
CFAS (Center For Physical Activity) Rigshospitalet
Jesper F Christensen, PhD
Role: PRINCIPAL_INVESTIGATOR
CFAS (Center For Physical Activity) Rigshospitalet
Claus Brandt, PhD
Role: PRINCIPAL_INVESTIGATOR
CFAS (Center For Physical Activity) Rigshospitalet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center For Physical Activity (CFAS)
Copenhagen Ø, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Amar, D., Lindholm, M. E., Norrbom, J., Wheeler, M. T., Rivas, M., & Ashley, E. A. (2020). Differential Response Trajectories to Acute Exercise in Blood and Muscle. SSRN Electronic Journal, 1-43. https://doi.org/10.2139/ssrn.3508810
Reference Type
BACKGROUND
Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975 Nov;35(7):609-16. No abstract available.
Reference Type
BACKGROUND
Bigley AB, Rezvani K, Chew C, Sekine T, Pistillo M, Crucian B, Bollard CM, Simpson RJ. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav Immun. 2014 Jul;39:160-71. doi: 10.1016/j.bbi.2013.10.030. Epub 2013 Nov 5.
Reference Type
BACKGROUND
Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ. 2014 Jan;21(1):5-14. doi: 10.1038/cdd.2013.26. Epub 2013 Apr 12.
Reference Type
BACKGROUND
Christensen JF, Simonsen C, Hojman P. Exercise Training in Cancer Control and Treatment. Compr Physiol. 2018 Dec 13;9(1):165-205. doi: 10.1002/cphy.c180016.
Reference Type
BACKGROUND
Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, Li Poon MM, Li J, Arakawa-Hoyt J, Shen Y, Fong L, Lanier LL, Farber DL. Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell. 2020 Feb 20;180(4):749-763.e13. doi: 10.1016/j.cell.2020.01.022. Epub 2020 Feb 13.
Reference Type
BACKGROUND
Ghanemi A, St-Amand J. Interleukin-6 as a "metabolic hormone". Cytokine. 2018 Dec;112:132-136. doi: 10.1016/j.cyto.2018.06.034. Epub 2018 Jul 6.
Reference Type
BACKGROUND
Gjevestad GO, Holven KB, Ulven SM. Effects of Exercise on Gene Expression of Inflammatory Markers in Human Peripheral Blood Cells: A Systematic Review. Curr Cardiovasc Risk Rep. 2015;9(7):34. doi: 10.1007/s12170-015-0463-4.
Reference Type
BACKGROUND
Gupta P, Bigley AB, Markofski M, Laughlin M, LaVoy EC. Autologous serum collected 1 h post-exercise enhances natural killer cell cytotoxicity. Brain Behav Immun. 2018 Jul;71:81-92. doi: 10.1016/j.bbi.2018.04.007. Epub 2018 Apr 12.
Reference Type
BACKGROUND
Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol. 2004 Dec 1;173(11):6547-63. doi: 10.4049/jimmunol.173.11.6547.
Reference Type
BACKGROUND
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011 Feb 20;29(6):726-32. doi: 10.1200/JCO.2010.31.5226. Epub 2011 Jan 4.
Reference Type
BACKGROUND
Larrabee RC. Leucocytosis after violent Exercise. J Med Res. 1902 Jan;7(1):76-82. No abstract available.
Reference Type
BACKGROUND
Larsen SK, Gao Y, Basse PH. NK cells in the tumor microenvironment. Crit Rev Oncog. 2014;19(1-2):91-105. doi: 10.1615/critrevoncog.2014011142.
Reference Type
BACKGROUND
Lukaski HC. Soft tissue composition and bone mineral status: evaluation by dual-energy X-ray absorptiometry. J Nutr. 1993 Feb;123(2 Suppl):438-43.
Reference Type
BACKGROUND
Macpherson RE, Huber JS, Frendo-Cumbo S, Simpson JA, Wright DC. Adipose Tissue Insulin Action and IL-6 Signaling after Exercise in Obese Mice. Med Sci Sports Exerc. 2015 Oct;47(10):2034-42. doi: 10.1249/MSS.0000000000000660.
Reference Type
BACKGROUND
Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009 Dec 14;169(22):2102-8. doi: 10.1001/archinternmed.2009.412.
Reference Type
BACKGROUND
Nieman DC, Miller AR, Henson DA, Warren BJ, Gusewitch G, Johnson RL, Davis JM, Butterworth DE, Nehlsen-Cannarella SL. Effects of high- vs moderate-intensity exercise on natural killer cell activity. Med Sci Sports Exerc. 1993 Oct;25(10):1126-34.
Reference Type
BACKGROUND
Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol. 1999 Feb 15;515 ( Pt 1)(Pt 1):287-91. doi: 10.1111/j.1469-7793.1999.287ad.x.
Reference Type
BACKGROUND
Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev. 2000 Jul;80(3):1055-81. doi: 10.1152/physrev.2000.80.3.1055.
Reference Type
BACKGROUND
Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, Johannesen HH, Becker JC, Pedersen KS, Dethlefsen C, Nielsen J, Gehl J, Pedersen BK, Thor Straten P, Hojman P. Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metab. 2016 Mar 8;23(3):554-62. doi: 10.1016/j.cmet.2016.01.011. Epub 2016 Feb 16.
Reference Type
BACKGROUND
Perez SA, Mahaira LG, Demirtzoglou FJ, Sotiropoulou PA, Ioannidis P, Iliopoulou EG, Gritzapis AD, Sotiriadou NN, Baxevanis CN, Papamichail M. A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival. Blood. 2005 Jul 1;106(1):158-66. doi: 10.1182/blood-2004-08-3232. Epub 2005 Mar 8.
Reference Type
BACKGROUND
Radom-Aizik S, Zaldivar F, Haddad F, Cooper DM. Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults. J Appl Physiol (1985). 2013 Mar 1;114(5):628-36. doi: 10.1152/japplphysiol.01341.2012. Epub 2013 Jan 3.
Reference Type
BACKGROUND
Rooney BV, Bigley AB, LaVoy EC, Laughlin M, Pedlar C, Simpson RJ. Lymphocytes and monocytes egress peripheral blood within minutes after cessation of steady state exercise: A detailed temporal analysis of leukocyte extravasation. Physiol Behav. 2018 Oct 1;194:260-267. doi: 10.1016/j.physbeh.2018.06.008. Epub 2018 Jun 7.
Reference Type
BACKGROUND
Schlahsa L, Jaimes Y, Blasczyk R, Figueiredo C. Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function. Transfusion. 2011 Feb;51(2):293-305. doi: 10.1111/j.1537-2995.2010.02820.x. Epub 2010 Aug 16.
Reference Type
BACKGROUND
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5.
Reference Type
BACKGROUND
Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention. Lyon (FR): International Agency for Research on Cancer; 2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK606505/
Reference Type
BACKGROUND
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008 May;9(5):503-10. doi: 10.1038/ni1582.
Reference Type
BACKGROUND
Wang Y, Jacobs EJ, Gapstur SM, Maliniak ML, Gansler T, McCullough ML, Stevens VL, Patel AV. Recreational Physical Activity in Relation to Prostate Cancer-specific Mortality Among Men with Nonmetastatic Prostate Cancer. Eur Urol. 2017 Dec;72(6):931-939. doi: 10.1016/j.eururo.2017.06.037. Epub 2017 Jul 12.
Reference Type
BACKGROUND
Weber MM, Michl P, Auernhammer CJ, Engelhardt D. Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells. Endocrinology. 1997 May;138(5):2207-10. doi: 10.1210/endo.138.5.5239.
Reference Type
BACKGROUND
Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol. 2006 Dec;80(6):1529-41. doi: 10.1189/jlb.0306191. Epub 2006 Sep 11.
Reference Type
BACKGROUND
Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-56. doi: 10.1016/s0065-230x(03)90004-2.
Reference Type
BACKGROUND
Yamada M, Suzuki K, Kudo S, Totsuka M, Nakaji S, Sugawara K. Raised plasma G-CSF and IL-6 after exercise may play a role in neutrophil mobilization into the circulation. J Appl Physiol (1985). 2002 May;92(5):1789-94. doi: 10.1152/japplphysiol.00629.2001.
Reference Type
BACKGROUND
Zimmer P, Schenk A, Kieven M, Holthaus M, Lehmann J, Lovenich L, Bloch W. Exercise induced alterations in NK-cell cytotoxicity - methodological issues and future perspectives. Exerc Immunol Rev. 2017;23:66-81.
Reference Type
BACKGROUND
Dorling J, Broom DR, Burns SF, Clayton DJ, Deighton K, James LJ, King JA, Miyashita M, Thackray AE, Batterham RL, Stensel DJ. Acute and Chronic Effects of Exercise on Appetite, Energy Intake, and Appetite-Related Hormones: The Modulating Effect of Adiposity, Sex, and Habitual Physical Activity. Nutrients. 2018 Aug 22;10(9):1140. doi: 10.3390/nu10091140.
Reference Type
BACKGROUND
Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000 Nov 15;529 Pt 1(Pt 1):237-42. doi: 10.1111/j.1469-7793.2000.00237.x.
Reference Type
BACKGROUND
Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001 Mar;933:222-34. doi: 10.1111/j.1749-6632.2001.tb05827.x.
Reference Type
BACKGROUND
van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, de Vries EG. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994 Sep 1;84(5):1434-41.
Reference Type
BACKGROUND
Timper K, Denson JL, Steculorum SM, Heilinger C, Engstrom-Ruud L, Wunderlich CM, Rose-John S, Wunderlich FT, Bruning JC. IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep. 2017 Apr 11;19(2):267-280. doi: 10.1016/j.celrep.2017.03.043.
Reference Type
BACKGROUND
Lang Lehrskov L, Lyngbaek MP, Soederlund L, Legaard GE, Ehses JA, Heywood SE, Wewer Albrechtsen NJ, Holst JJ, Karstoft K, Pedersen BK, Ellingsgaard H. Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control. Cell Metab. 2018 Jun 5;27(6):1201-1211.e3. doi: 10.1016/j.cmet.2018.04.008. Epub 2018 May 3.
Reference Type
BACKGROUND
Ellingsgaard H, Seelig E, Timper K, Coslovsky M, Soederlund L, Lyngbaek MP, Wewer Albrechtsen NJ, Schmidt-Trucksass A, Hanssen H, Frey WO, Karstoft K, Pedersen BK, Boni-Schnetzler M, Donath MY. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia. 2020 Feb;63(2):362-373. doi: 10.1007/s00125-019-05045-y. Epub 2019 Dec 3.
Reference Type
BACKGROUND
Begg DP, Woods SC. The endocrinology of food intake. Nat Rev Endocrinol. 2013 Oct;9(10):584-97. doi: 10.1038/nrendo.2013.136. Epub 2013 Jul 23.
Reference Type
BACKGROUND
Medhus AW, Sandstad O, Bredesen J, Husebye E. Delay of gastric emptying by duodenal intubation: sensitive measurement of gastric emptying by the paracetamol absorption test. Aliment Pharmacol Ther. 1999 May;13(5):609-20. doi: 10.1046/j.1365-2036.1999.00519.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
jr. nr. H-20028611
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
NK Cells Treatment for COVID-19
NCT04280224
COMPLETED
PHASE1
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918
COMPLETED
PHASE1
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
NCT06935266
COMPLETED
PHASE1
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996
UNKNOWN
PHASE1/PHASE2
Study to Asses Efficacy of Intralymphatic Immunotherapy
NCT01166269
COMPLETED
PHASE2/PHASE3
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
NCT04578210
COMPLETED
PHASE1/PHASE2
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
NCT04365101
UNKNOWN
PHASE1/PHASE2
Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency
NCT00011141
COMPLETED
NA
Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors
NCT07258160
RECRUITING
PHASE2
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673
UNKNOWN
PHASE1/PHASE2
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524
COMPLETED
PHASE1/PHASE2
T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects
NCT02085759
COMPLETED
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers
NCT01299662
COMPLETED
PHASE1
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935
RECRUITING
PHASE1/PHASE2
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
NCT02049489
COMPLETED
PHASE1
T Cells Response to SARS COV 2 Peptides
NCT04573348
UNKNOWN
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NCT06193902
RECRUITING
PHASE1/PHASE2
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
NCT06052436
RECRUITING
PHASE1/PHASE2
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
NCT05862324
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
NCT03515252
COMPLETED
PHASE1
Immune Cell Response to Stimuli
NCT00397280
RECRUITING
Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients
NCT00940004
COMPLETED
PHASE1/PHASE2
The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement
NCT04940910
UNKNOWN
NA
Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19
NCT04797975
WITHDRAWN
PHASE1/PHASE2
Dendritic Cell Based Therapy of Renal Cell Carcinoma
NCT00197860
COMPLETED
PHASE1/PHASE2